Age-Related Macular Degeneration (AMD) Treatment in Red Bank, NJ
Age-related macular degeneration is a leading cause of central vision loss in adults over 50. At Crystal Eyecare in Red Bank, NJ, we provide thorough evaluations, education, and coordinated care to help you understand AMD, monitor changes, and access appropriate treatment with our ophthalmology partners when needed.
Call now - see what you have been missing. Request an eye exam
What Is AMD?
AMD affects the macula, the area of the retina that provides sharp, straight-ahead vision, and it is a leading cause of central vision loss in older adults (Fleckenstein et al., 2024). It has two main forms. Dry AMD is the more common form and involves gradual changes in the macula, including small deposits called drusen; in its advanced stage, patches of the retina thin and waste away, a change called geographic atrophy. Wet (neovascular) AMD involves abnormal blood vessels that can leak and scar, which may cause faster vision loss.
Common Symptoms
- Blurred or fuzzy central vision
- Distortion of straight lines
- Dark or empty spots in central vision
- Difficulty reading, recognizing faces, or seeing fine detail
Risk Factors
AMD is multifactorial, shaped by both genetic and environmental factors (Mitchell et al., 2018):
- Age over 50
- Family history or genetic factors
- Cigarette smoking, the single most important modifiable risk factor (Velilla et al., 2013)
- Cardiometabolic factors such as hypertension or elevated cholesterol
How We Diagnose and Monitor
Your visit may include a dilated retinal exam, retinal imaging such as optical coherence tomography (OCT), visual function testing, and discussion of risk factors and lifestyle. We educate you on signs that require prompt attention, and we coordinate referrals for treatments such as intravitreal anti-VEGF injections when indicated for neovascular AMD.
Evidence-Based Treatment Overview
- AREDS2 nutritional formula for intermediate AMD: for patients who meet clinical criteria, the AREDS2 formula can reduce the risk of progression to advanced AMD. It replaces beta-carotene with lutein and zeaxanthin to avoid the higher lung-cancer risk seen with beta-carotene in current and former smokers (AREDS2 Research Group, 2013). Your provider will advise whether it is appropriate for you.
- Anti-VEGF therapy for wet AMD: intravitreal medications are the first-line treatment for neovascular AMD and stabilize or improve vision for many patients (Fleckenstein et al., 2024). Treatment schedules vary by drug and clinical response.
- Lifestyle support: smoking cessation, a balanced diet rich in leafy greens and fish, regular exercise, and control of blood pressure and cholesterol support overall eye health.
- Home monitoring: report new distortion or a sudden change in central vision promptly. An Amsler grid can help, but its sensitivity is limited, so a normal result does not rule out a problem. Keep up with regular eye exams and seek evaluation if you notice any change (Bjerager et al., 2023).
Our Role in Your Care
Crystal Eyecare provides comprehensive evaluations, education, and ongoing monitoring. When specialist treatment is needed, we coordinate care with trusted retinal physicians and continue local follow-up to help protect your vision.
Call now - see what you have been missing. Request an eye exam
References
- Age-Related Eye Disease Study 2 (AREDS2) Research Group. (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA, 309(19), 2005-2015. https://doi.org/10.1001/jama.2013.4997
- Bjerager, J., Schneider, M., Potapenko, I., et al. (2023). Diagnostic accuracy of the Amsler grid test for detecting neovascular age-related macular degeneration: A systematic review and meta-analysis. JAMA Ophthalmology, 141(4), 315-323. https://doi.org/10.1001/jamaophthalmol.2022.6396
- Fleckenstein, M., Schmitz-Valckenberg, S., & Chakravarthy, U. (2024). Age-related macular degeneration: A review. JAMA, 331(2), 147-157. https://doi.org/10.1001/jama.2023.26074
- Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018). Age-related macular degeneration. The Lancet, 392(10153), 1147-1159. https://doi.org/10.1016/S0140-6736(18)31550-2
- Velilla, S., García-Medina, J. J., García-Layana, A., et al. (2013). Smoking and age-related macular degeneration: Review and update. Journal of Ophthalmology, 2013, 895147. https://doi.org/10.1155/2013/895147